Literature DB >> 4074422

Physico-chemical properties and stability of cilostazol.

T Shimizu, T Osumi, K Niimi, K Nakagawa.   

Abstract

The physico-chemical properties of cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-qui nolinone, OPC-13013), a new potential antithrombotic and vasodilating drug, were studied by clarifying its elemental composition, melting point, spectra (UV, IR, NMR and mass), X-ray diffraction pattern, thermal properties, solubilities and partition coefficient. Analytical test methods such as HPLC and TLC were established for use in stability tests, and the stability study of cilostazol in an aqueous solution (acid and base) and in a solid form was carried out. Cilostazol was shown to be stable with no changes from the initial values.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4074422

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

1.  Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.

Authors:  S L Bramer; W P Forbes
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

2.  Effect of omeprazole on the metabolism of cilostazol.

Authors:  A Suri; S L Bramer
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

3.  A systematic approach to design and prepare solid dispersions of poorly water-soluble drug.

Authors:  Sanjay Verma; Varma S Rudraraju
Journal:  AAPS PharmSciTech       Date:  2014-02-22       Impact factor: 3.246

4.  Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.

Authors:  Sanjay Verma; Varma S Rudraraju
Journal:  AAPS PharmSciTech       Date:  2015-02-12       Impact factor: 3.246

5.  Disintegration mediated controlled release supersaturating solid dispersion formulation of an insoluble drug: design, development, optimization, and in vitro evaluation.

Authors:  Sanjay Verma; Varma S Rudraraju
Journal:  AAPS PharmSciTech       Date:  2014-09-05       Impact factor: 3.246

6.  Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers.

Authors:  Yo Han Kim; Jong-Lyul Ghim; Jin Ah Jung; Sang-Heon Cho; Sangmin Choe; Hee Youn Choi; Kyun-Seop Bae; Hyeong-Seok Lim
Journal:  Drug Des Devel Ther       Date:  2015-07-09       Impact factor: 4.162

7.  Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications.

Authors:  Marek Rychter; Anna Baranowska-Korczyc; Bartłomiej Milanowski; Marcin Jarek; Barbara M Maciejewska; Emerson L Coy; Janina Lulek
Journal:  Pharm Res       Date:  2018-01-16       Impact factor: 4.200

8.  A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.

Authors:  Emilia Jakubowska; Bartłomiej Milanowski; Janina Lulek
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

9.  Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate.

Authors:  Jae Hong Seo; Jung Bae Park; Woong-Kee Choi; Sunhwa Park; Yun Jin Sung; Euichaul Oh; Soo Kyung Bae
Journal:  Drug Des Devel Ther       Date:  2015-07-30       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.